Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer
Status:
Unknown status
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
Triple-negative breast cancer (TNBC) is a special type of breast cancer, endocrine therapy
and targeted therapy are completely ineffective, chemotherapy is currently the only effective
treatment. How to improve postoperative pathologic complete response（pCR）of neoadjuvant
chemotherapy is critical problem to prolong overall survival (OS) of TNBC patients. Apatinib
is a new oral small molecule tyrosine protease inhibitor, it is effective in inhibiting
angiogenesis with a very low concentration. So the standard neoadjuvant chemotherapy regimen
of docetaxel and carboplatin combined with apatinib may improve the postoperative PCR and OS
of TNBC patients. Safety and tolerability assessed by number of grade 3 and 4 toxicities and
hospitalizations.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Guangdong General Hospital Guangdong Provincial People's Hospital